Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Multidetector-row computed tomography
Neoadjuvant therapy
Pancreatic cancer
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
31
05
2021
accepted:
25
08
2021
revised:
25
07
2021
pubmed:
20
10
2021
medline:
17
3
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
To derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT). This retrospective study included 112 patients with PDAC who underwent dynamic contrast-enhanced CT before and after neoadjuvant CRT. A 5-point score was used to determine arterial involvement (A score; 1 = no involvement, 2 = haziness, 3 = abutment, 4 = encasement, 5 = deformity) and 4-point score evaluating resectability status (R score; 1 = resectable, 2 = borderline resectable [BR] with venous involvement, 3 = BR with arterial involvement, 4 = locally advanced [LA]). A score before and after CRT were summed with R score before and after CRT to compute the AR score (AR The AR A composite score which incorporates degree of arterial involvement and resectability status before and after neoadjuvant CRT is associated with R0 resection and discriminates between R0 and R1 resections in PDAC. • A scoring system incorporating arterial involvement and resectability status was associated with R0 resection. • AR
Identifiants
pubmed: 34665317
doi: 10.1007/s00330-021-08304-y
pii: 10.1007/s00330-021-08304-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2470-2480Informations de copyright
© 2021. European Society of Radiology.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33
doi: 10.3322/caac.21654
Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512
doi: 10.1200/JCO.2013.50.7657
Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17
doi: 10.1097/SLA.0000000000000867
Heestand GM, Murphy JD, Lowy AM (2015) Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 33:1770–1778
doi: 10.1200/JCO.2014.59.7930
Michelakos T, Pergolini I, Castillo CF et al (2019) Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg 269:733–740
doi: 10.1097/SLA.0000000000002600
Kluger MD, Rashid MF, Rosario VL et al (2018) Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg 22:235–241
doi: 10.1007/s11605-017-3556-1
Neoptolemos JP, Stocken DD, Dunn JA et al (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768
doi: 10.1097/00000658-200112000-00007
NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 2. 2021. pancreatic.pdf ( nccn.org ). Accessed 27 March 2021
Hong SB, Lee SS, Kim JH et al (2018) Pancreatic cancer CT: prediction of resectability according to NCCN criteria. Radiology 289:710–718
doi: 10.1148/radiol.2018180628
Noda Y, Goshima S, Kawada H et al (2018) Modified national comprehensive cancer network criteria for assessing resectability of pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 210:1252–1258
doi: 10.2214/AJR.17.18595
Xia BT, Fu B, Wang J et al (2017) Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol 115:376–383
doi: 10.1002/jso.24538
Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116
doi: 10.1007/s00330-016-4632-8
Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94:2511–2516
doi: 10.1002/cncr.10492
Ryan R, Gibbons D, Hyland JM et al (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141–146
doi: 10.1111/j.1365-2559.2005.02176.x
Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270:248–260
doi: 10.1148/radiol.13131184
Murakami Y, Satoi S, Sho M et al (2015) National comprehensive cancer network resectability status for pancreatic carcinoma predicts overall survival. World J Surg 39:2306–2314
doi: 10.1007/s00268-015-3096-3
McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22:276–282
doi: 10.11613/BM.2012.031
Martinez-Camblor P, Pardo-Fernandez JC (2019) The Youden index in the generalized receiver operating characteristic curve context. Int J Biostat 15(1). https://doi.org/10.1515/ijb-2018-0060
Yoo C, Hwang I, Song TJ et al (2020) FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Ther Adv Med Oncol 12:1758835920953294
doi: 10.1177/1758835920953294
Matsumoto I, Kamei K, Omae K et al (2019) FOLFIRINOX for locally advanced pancreatic cancer: results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology 19:296–301
doi: 10.1016/j.pan.2019.01.001
Choi YH, Lee SH, You MS et al (2020) Prognostic factors for patients with borderline resectable or locally advanced pancreatic cancer receiving neoadjuvant FOLFIRINOX. Gut Liver. https://doi.org/10.5009/gnl19182
doi: 10.5009/gnl19182
pubmed: 33024061
pmcid: 8283296